# Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

> **NCT01693614** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 72 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

## Interventions

- **DRUG:** Buparlisib

## Key facts

- **NCT ID:** NCT01693614
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-02-28
- **Primary completion:** 2017-07-21
- **Final completion:** 2017-07-21
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2018-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01693614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01693614, "Safety and Efficacy of BKM120 in Relapsed and Refractory NHL". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01693614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*